The Department of Health and Human Services (HHS) is once again seeking feedback on a potential redesign of its 340B drug rebate model, following a series of legal challenges that effectively halted the initial implementation. This move comes as the agency attempts to navigate a complex landscape of drug pricing and access, particularly for vulnerable populations served by hospitals participating in the 340B program.
On February 13, the Health Resources and Services Administration (HRSA) issued a request for information (RFI) to gather input from stakeholders on a potential rebate-based model under the 340B Drug Pricing Program. The agency is accepting comments through March 19, 2026, as it evaluates whether to launch a pilot program and, if so, how it might be structured. The 340B program is a critical component of the healthcare safety net, providing discounted drugs to hospitals that serve a high proportion of low-income and uninsured patients.
The American Hospital Association (AHA) has welcomed the opportunity to provide input, but also cautioned against policies that could increase costs for hospitals serving vulnerable communities. “The AHA welcomes HRSA’s attempt to gather detailed information about the impact of a rebate model,” said Aimee Kuhlman, AHA vice president of advocacy and grassroots, in a statement. “We hope that after careful consideration of comments from 340B hospitals and other stakeholders, HRSA will recognize that imposing hundreds of millions of dollars in costs on hospitals serving rural and underserved communities is not a sound policy.”
Legal Challenges Prompted Re-evaluation
The current effort to redesign the rebate model follows a series of setbacks for the initial program announced in August 2025. That program aimed to shift 340B hospitals from receiving upfront discounts on drugs to a rebate model, requiring them to pay full market prices and then seek reimbursement. The AHA and other plaintiffs sued the HHS, arguing the change would create significant financial burdens and potentially jeopardize access to care for those who rely on 340B hospitals.
The U.S. District Court for the District of Maine issued a preliminary injunction on December 29, 2025, halting the implementation of the program. The 1st U.S. Circuit Court of Appeals subsequently denied the government’s request for a stay on January 7, 2026. Facing these legal obstacles, HHS filed a motion on February 5, 2026, stating that further litigation would not be “fruitful” and requesting the court to remand the issue back to HRSA. The district court granted this request on February 10, 2026, effectively vacating the original program and its approvals.
What to Expect in a New Model
Any new rebate program developed by HRSA will be subject to a formal process, including public notice, a comment period, and a delayed effective date of at least 90 days after manufacturer approvals are announced, according to reporting from Modern Healthcare. This indicates a more deliberate and transparent approach than the initial attempt, which faced criticism for its rapid implementation and perceived lack of stakeholder engagement.
The 340B program has been a subject of ongoing debate, with pharmaceutical companies arguing that the discounts are too generous and contribute to higher drug prices for other payers. Hospitals, however, maintain that the program is essential for providing affordable care to vulnerable patients. The outcome of this latest review by HRSA will likely have significant implications for both hospitals and the pharmaceutical industry.
As HRSA gathers information and considers potential changes, stakeholders will be closely watching to notice how the agency balances the competing interests and ensures that any new model effectively serves the needs of both patients and hospitals. The comments submitted by March 19 will be crucial in shaping the future of the 340B program.
Disclaimer: This article provides informational content and should not be considered medical or financial advice. Consult with a qualified healthcare professional or financial advisor for personalized guidance.
What are your thoughts on the future of the 340B program? Share your comments below.
